|
|
- In vitro preclinical testing of nonoxynol-9 as potential anti-human immunodeficiency virus microbicide: a retrospective analysis of results from five laboratories Beer BE, Doncel GF, Krebs FC, Shattock RJ, Fletcher PS, Buckheit RW Jr, Watson K, Dezzutti CS, Cummins JE, Bromley E, Richardson-Harman N, Pallansch LA, Lackman-Smith C, Osterling C, Mankowski M, Miller SR, Catalone BJ, Welsh PA, Howett MK, Wigdahl B, Turpin JA, Reichelderfer P. Antimicrob Agents Chemother. 2006 Feb;50(2):713-23
- View recently accepted abstracts/poster presentations.
- Search journal publications.
- Quality Assurance Program References:
- Estimation of Serum-Free 50-Percent Inhibitory Concentrations for Human Immunodeficiency Virus Protease Inhibitors Lopinavir and Ritonavir Hickman D, Vasavanonda S, Nequist G, Colletti L, Kati WM, Bertz R, Hsu A, Kempf DJ ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2004, p. 2911–2917
- Evaluation of a Quality Assurance Program for Quantitation of Human Immunodeficiency Virus Type 1 RNA in Plasma by the AIDS Clinical Trials Group Virology Laboratories Yen-Lieberman B, Brambilla D, Jackson B, Bremer J, Coombs R, Cronin M, Herman S, Katzenstein D, Leung S, Lin HJ, Palumbo P, Rasheed S, Todd J, Vahey M, Reichelderfer P. J Clin Microbiol. 1996 Nov;34(11):2695-701
- A menstrual cycle pattern for cytokine levels exists in HIV-positive women: implication for HIV vaginal and plasma shedding.Al-Harthi L, Kovacs A, Coombs RW, Reichelderfer PS, Wright DJ, Cohen MH, Cohn J, Cu-Uvin S, Watts H, Lewis S, Beckner S, Landay A; WHS 001 Study Team. AIDS. 2001 Aug 17;15(12):1535-43
- Variation of Human Immunodeficiency Virus Type 1 Viral RNA Levels in the Female Genital Tract: Implications for Applying Measurements to Individual Women. Coombs RW, Wright DJ, Reichelderfer PS, Burns DN, Cohn J, Cu-Uvin S, Baron PA, Cohen MH, Landay AL, Lewis S, Kovacs A; Women's Health Study 001 Team. J Infect Dis. 2001 Nov 1;184(9):1187-91. Epub 2001 Sep 13
- Multicenter Evaluation of Quantification Methods for Plasma Human Immunodeficiency Virus Type 1 RNA. Lin HJ, Myers LE, Yen-Lieberman B, Hollinger FB, Henrard D, Hooper CJ, Kokka R, Kwok S, Rasheed S, Vahey M, et al. J Infect Dis. 1994 Sep;170(3):553-62.
|
|
 |
